Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ATR inact mut |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04019327 | Phase Ib/II | Talazoparib + Temozolomide | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT04890613 | Phase I | CX-5461 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Recruiting | USA | CAN | 0 |
| NCT06844383 | Phase II | Enzalutamide + Talazoparib Talazoparib | A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) | Recruiting | USA | 0 |
| NCT02401347 | Phase II | Talazoparib | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | Completed | USA | 0 |
| NCT03012321 | Phase II | Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | Active, not recruiting | USA | 0 |
| NCT04821622 | Phase III | Enzalutamide Enzalutamide + Talazoparib | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Active, not recruiting | USA | TUR | SVK | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BGR | BEL | AUS | ARG | 9 |
| NCT03377556 | Phase II | Talazoparib | Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
| NCT03344965 | Phase II | Olaparib | Olaparib in Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
| NCT05038839 | Phase I | Cabozantinib + Pamiparib | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | Active, not recruiting | USA | 0 |
| NCT04550494 | Phase II | Talazoparib | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Recruiting | USA | 0 |
| NCT04266912 | Phase Ib/II | Avelumab + Berzosertib | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | Active, not recruiting | USA | 0 |